Skip to main
ASTH
ASTH logo

ASTH Stock Forecast & Price Target

ASTH Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Astrana Health Inc. has demonstrated a significant stock price increase of 34% since the 1Q24 report, substantially outpacing the S&P index's 6% rise, indicating strong market confidence in the company's growth prospects. The organization has prioritized profitable growth and maintained a conservative approach to risk accrual in its Accountable Care Organization (ACO) programs, enhancing its operational visibility and stability. With an expected growth rate of over 15% and ongoing improvements in EBITDA as the company shifts Medicare and Medicaid patients to a full-risk model, combined with strong brand recognition, Astrana Health is positioned for continued financial success.

Bears say

Astrana Health Inc faces significant challenges, including a notable 40,000-member decline in Care Partners enrollment, which complicates its overall member growth trajectory. Negative trends in key performance metrics, alongside potential setbacks in provider value-based care implementations and the impact of Medicaid redeterminations, heighten the risk of decreased margins and stagnant revenue growth. Furthermore, competition in the value-based care sector and uncertainties related to large partnerships and healthcare utilization further contribute to a cautious outlook for the company.

ASTH has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Astrana Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Astrana Health Inc (ASTH) Forecast

Analysts have given ASTH a Strong Buy based on their latest research and market trends.

According to 1 analysts, ASTH has a Strong Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Astrana Health Inc (ASTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.